These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 18627322)

  • 21. Effectiveness of ezetimibe alone or in combination with twice a week Atorvastatin (10 mg) for statin intolerant high-risk patients.
    Athyros VG; Tziomalos K; Kakafika AI; Koumaras H; Karagiannis A; Mikhailidis DP
    Am J Cardiol; 2008 Feb; 101(4):483-5. PubMed ID: 18312762
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of lipid-lowering drugs on reverse cholesterol transport gene expressions in peripheral blood mononuclear and HepG2 cells.
    Genvigir FD; Rodrigues AC; Cerda A; Arazi SS; Willrich MA; Oliveira R; Hirata MH; Dorea EL; Bernik MM; Curi R; Hirata RD
    Pharmacogenomics; 2010 Sep; 11(9):1235-46. PubMed ID: 20860464
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of ezetimibe on adipose tissue hormones in patients with isolated hypercholesterolemia.
    Krysiak R; Żmuda W; Okopień B
    Pharmacol Rep; 2014 Jun; 66(3):442-7. PubMed ID: 24905521
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of atorvastatin and ezetimibe on endothelial function in dyslipidemic patients with chronic kidney disease.
    Ishimitsu T; Ohno E; Ueno Y; Onoda S; Nagase A; Ohira T; Nakano N; Satonaka H
    Clin Exp Nephrol; 2014 Oct; 18(5):704-10. PubMed ID: 24198051
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness of low-intensity atorvastatin 5 mg and ezetimibe 10 mg combination therapy compared with moderate-intensity atorvastatin 10 mg monotherapy: A randomized, double-blinded, multi-center, phase III study.
    Lee SA; Hong SJ; Sung JH; Kim KS; Kim SH; Cho JM; Chun SW; Lee SR; Kim CS; Kim TN; Kim DH; Park HC; Kim BJ; Kim HS; Choi JY; Hong YJ; Chung JW; Yoon SB; Lee SH; Lee CW
    Medicine (Baltimore); 2023 Nov; 102(47):e36122. PubMed ID: 38013289
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
    Bennett S; Sager P; Lipka L; Melani L; Suresh R; Veltri E;
    J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets.
    McCormack T; Harvey P; Gaunt R; Allgar V; Chipperfield R; Robinson P;
    Int J Clin Pract; 2010 Jul; 64(8):1052-61. PubMed ID: 20487050
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combinational effects of farnesoid X receptor antagonist and statin on plasma lipid levels and low-density lipoprotein clearance in guinea pigs.
    Amano Y; Ishikawa E; Shinozawa E; Shimada M; Miura S; Adachi R; Tozawa R
    Life Sci; 2014 Jul; 108(1):7-12. PubMed ID: 24805868
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
    Alvarez-Sala LA; Cachofeiro V; Masana L; Suarez C; Pinilla B; Plana N; Trias F; Moreno MA; Gambus G; Lahera V; Pintó X
    Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome.
    Simons L; Tonkon M; Masana L; Maccubbin D; Shah A; Lee M; Gumbiner B
    Curr Med Res Opin; 2004 Sep; 20(9):1437-45. PubMed ID: 15383192
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia.
    Blom DJ; Hala T; Bolognese M; Lillestol MJ; Toth PD; Burgess L; Ceska R; Roth E; Koren MJ; Ballantyne CM; Monsalvo ML; Tsirtsonis K; Kim JB; Scott R; Wasserman SM; Stein EA;
    N Engl J Med; 2014 May; 370(19):1809-19. PubMed ID: 24678979
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of ezetimibe, simvastatin, atorvastatin, and ezetimibe-statin therapies on non-cholesterol sterols in patients with primary hypercholesterolemia.
    Assmann G; Kannenberg F; Ramey DR; Musliner TA; Gutkin SW; Veltri EP
    Curr Med Res Opin; 2008 Jan; 24(1):249-59. PubMed ID: 18053317
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial.
    Pearson TA; Denke MA; McBride PE; Battisti WP; Brady WE; Palmisano J
    Mayo Clin Proc; 2005 May; 80(5):587-95. PubMed ID: 15887425
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia.
    Gagné C; Gaudet D; Bruckert E;
    Circulation; 2002 May; 105(21):2469-75. PubMed ID: 12034651
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of the effects of combination atorvastatin (40 mg) + ezetimibe (10 mg) versus atorvastatin (40 mg) alone on secretory phospholipase A2 activity in patients with stable coronary artery disease or coronary artery disease equivalent.
    Azar M; Valentin E; Badaoui G; Kassab R; Sarkis A; Azar RR
    Am J Cardiol; 2011 Jun; 107(11):1571-4. PubMed ID: 21439529
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and efficacy of ezetimibe added to atorvastatin versus up titration of atorvastatin to 40 mg in Patients > or = 65 years of age (from the ZETia in the ELDerly [ZETELD] study).
    Zieve F; Wenger NK; Ben-Yehuda O; Constance C; Bird S; Lee R; Hanson ME; Jones-Burton C; Tershakovec AM
    Am J Cardiol; 2010 Mar; 105(5):656-63. PubMed ID: 20185012
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy.
    Pearson TA; Ballantyne CM; Veltri E; Shah A; Bird S; Lin J; Rosenberg E; Tershakovec AM
    Am J Cardiol; 2009 Feb; 103(3):369-74. PubMed ID: 19166691
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study.
    Roeters van Lennep HW; Liem AH; Dunselman PH; Dallinga-Thie GM; Zwinderman AH; Jukema JW
    Curr Med Res Opin; 2008 Mar; 24(3):685-94. PubMed ID: 18226326
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synergistic effect of ezetimibe addition on coronary atheroma regression in patients with prior statin therapy: Subanalysis of PRECISE-IVUS trial.
    Tsujita K; Yamanaga K; Komura N; Sakamoto K; Sugiyama S; Sumida H; Shimomura H; Yamashita T; Oka H; Nakao K; Nakamura S; Ishihara M; Matsui K; Sakaino N; Nakamura N; Yamamoto N; Koide S; Matsumura T; Fujimoto K; Tsunoda R; Morikami Y; Matsuyama K; Oshima S; Kaikita K; Hokimoto S; Ogawa H;
    Eur J Prev Cardiol; 2016 Sep; 23(14):1524-8. PubMed ID: 27296705
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study).
    Robinson JG; Ballantyne CM; Grundy SM; Hsueh WA; Parving HH; Rosen JB; Adewale AJ; Polis AB; Tomassini JE; Tershakovec AM
    Am J Cardiol; 2009 Jun; 103(12):1694-702. PubMed ID: 19539078
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.